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1. Introduction
Chronic hepatitis caused by the hepatitis C virus (HCV) remains
a global health problem, as it is accompanied with high morbidity
and progression to life-threatening liver diseases. Worldwide, 80 mil-
lion people are currently chronically infected with this virus (Gower
et al., 2014; Hanafiah et al., 2013), which manifests into seven geno-
types (GTs) and > 50 subtypes (Smith et al., 2014). The former stan-
dard treatment with pegylated interferon-α (pegIFN-α) and ribavirin
(Hofmann and Zeuzem, 2011) has greatly improved the outcome of
HCV infections, although its success varied according to the genotype,
with the lowest sustained virological response (SVR) rates achieved in
HCV genotype 1 infected patients (Munir et al., 2010).
As genotype 1 infections prevail worldwide, these low SVR rates
resulted into the development of the direct acting antivirals (DAAs),
which specifically target HCV proteins such as NS3, NS5A and
NS5B. The first DAAs still needed to be administered in combina-
tion with pegIFN-α and ribavirin, since their success was hampered
by the fast selection of viral drug resistant variants (Barnard et al.,
2013; Chevaliez, 2011; Halfon and Locarnini, 2011; Pawlotsky, 2011;
Sullivan et al., 2013), especially when administered as monotherapy.
In order to tackle drug resistance development, combination therapy
strategies with multiple DAAs were introduced (Gane et al., 2010;
Zeuzem et al., 2012), consisting of regimens which no longer need to
be combined with interferon, and which all reach SVR rates of > 90%
in all HCV genotypes (Andreone et al., 2014; Jacobson et al., 2014;
Kowdley et al., 2013; Lawitz et al., 2013; Nelson et al., 2015).
http://dx.doi.org/10.1016/j.meegid.2016.06.050
1567-1348/© 2016 Published by Elsevier Ltd.
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Major advances have revolutionized the HCV antiviral treatment field, with interferon-free combinations of direct-acting
antivirals (DAAs) resulting into success rates of > 90% for all HCV genotypes. Nevertheless, viral eradication at a global
level stills remains challenging, stimulating the continued search for new affordable pan-genotypic drugs. To overcome
selection of drug resistant variants, targeting host proteins can be an attractive mechanism of action. Alisporivir (Debio
025) is a potent pan-genotypic host-targeting antiviral agent, acting on cyclophilin A, which is necessary for HCV repli-
cation. The efficacy and safety of three different oral doses of alisporivir in combination with pegylated interferon-α2a
given over a period of four weeks, was investigated in a randomized, double-blind and placebo-controlled phase IIa clin-
ical trial, in 90 treatment-naïve subjects infected with chronic hepatitis C, wherefrom 58 HCV1b samples were selected
for genetic sequencing purposes. Sequencing results were used to study the HCV genome for amino acid changes poten-
tially related with selective pressure and resistance to alisporivir. By comparing baseline and on-treatment sequences, a
large variation in proportion of amino acid changes was detected in all treatment arms. The NS5A variant D320E, which
was previously identified during in vitro resistance selection and resulted in 3.6-fold reduced alisporivir susceptibility,
emerged in two subjects in the alisporivir monotherapy arm. However, emergence of D320E appeared to be associated
only with concurrent viral load rebound in one subject with 0.8 log10 IU/ml increase in HCV RNA. In general, for all
datasets, low numbers of positions under positive selective pressure were observed, with no significant differences be-
tween naïve and treated sequences. Additionally, incomplete sequence information for some of the 22 patients and the
low number of individuals per treatment arm, is limiting the power to assess the association of alisporivir or interferon
treatment with the observed amino acid changes.
© 2016 Published by Elsevier Ltd.
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Nevertheless, viral eradication of HCV at a global level is still
hampered due to remaining challenges, such as the lack of a pre-
ventive vaccine. The high number of undiagnosed and untreated pa-
tients should be decreased, and special attention is required to spe-
cific risk groups for which high incidence rates of re-infection follow-
ing SVR were reported (De Vos and Kretzschmar, 2014; Hill et al.,
2015). The costs associated with these potent regimens are high, mak-
ing it unlikely that all HCV infected patients worldwide will get ac-
cess to treatment. Additionally, as the first instance of transmission
of a telaprevir resistant HCV has recently been described (Franco et
al., 2014), the impact of drug resistance in the HCV antiviral treat-
ment field is not fully uncovered, resulting into the need of continued
search towards new pan-genotypic antiviral drugs, such as cyclophilin
inhibitors (Baugh et al., 2013; Lee, 2013), especially in case of retreat-
ing patients who previously failed a regimen consisting of all three
DAA classes.
Instead of disrupting the replication complex by the inhibition of
viral proteins, targeting host proteins can be an attractive mechanism
of action (Nag et al., 2012). Cyclophilin A is essential for the HCV
replication cycle, as it interacts together with HCV non-structural pro-
teins to initiate the formation of the replication complex, however
whether or not a direct interaction is obliged, is not entirely under-
stood. Its inhibitor cyclosporine A (CsA) is a powerful albeit toxic anti
HCV drug (Buti et al., 2014; Chatterji et al., 2014; Griffel et al., 2012),
as it inhibits the peptidyl prolyl-isomerase activity of cyclophilin A
and blocks the phosphorylation of the NS5A protein by cyclophilin A.
The non-immunosuppressive CsA derivative alisporivir (Debio 025)
is a pan-genotypic HCV inhibitor (Crabbé et al., 2009; Flisiak et al.,
2012; Gallay and Lin, 2013), of which potency was demonstrated in
vitro (Coelmont et al., 2009; Paeshuyse et al., 2006), as well as in
clinical settings, particularly in HCV3 infected subjects (Flisiak et al.,
2008, 2009; Guedj et al., 2013; Pawlotsky et al., 2012). In a phase II
study, alisporivir combined with pegIFN-α2a and ribavirin achieved
superior viral cure in 76% of the chronically HCV1 infected patients,
in contrast to 55% in patients treated with pegIFN-α2a and ribavirin
alone (Flisiak et al., 2011).
Recently, alisporivir was explored as an interferon-free combina-
tion regimen with DAAs in HCV2 and 3 infected subjects, resulting
into SVR rates ranging from 80% to 85% (Pawlotsky et al., 2015).
Amino acid variants related to drug resistance have been reported for
both drugs, alisporivir and pegIFN-α2a. For alisporivir a limited num-
ber of reports are available, and they describe a few amino acid sub-
stitutions in the HCV genome, mainly in the NS5A region (Arai et al.,
2014; Coelmont et al., 2010; Garcia-Rivera et al., 2012). With regard
to pegIFN-α2a, the interferon sensitivity-determining region (ISDR)
and the interferon ribavirin resistance-determining region (IRRDR),
both in the NS5A protein, are well known to play a role in the resis-
tance pathways of interferon (El-Shamy et al., 2011; Hayashi et al.,
2011; Kozuka et al., 2012).
We present here a genetic sequencing analysis of the effects of
alisporivir on HCV evolution using HCV1b samples from an ex-
ploratory phase II clinical trial, where the safety and efficacy of three
different oral doses of alisporivir in combination with pegIFN-α2a
was investigated in treatment-naïve subjects infected with HCV geno-
types 1 to 4, in a randomized, double-blind and placebo-controlled set-
ting (DEB-025-HCV-203) over a time period of four weeks (Flisiak
et al., 2009). From all four cohorts, the best viral response was ob-
tained in subjects treated with 600 or 1000 mg alisporivir combined
with 180 mcg/week pegIFN-α2a. In patients with genotypes 1 and
4, the 600- and 1000-mg combination treatments induced a contin-
uous decrease in viral load that reached − 4.61 ± 1.88 and
− 4.75 ± 2.19 log10 IU/ml at week 4, respectively. In patients infected
with HCV genotypes 2 and 3, HCV RNA levels at week 4 were re-
duced by − 5.91 ± 1.11 and − 5.89 ± 0.43 log10 IU/ml, respectively,
with the same treatment regimens. Twenty-five HCV1b infected sub-
jects were selected for genetic sequencing, based on HCV viral load
evolution during treatment and after end of therapy (< 2 log IU/ml vi-
ral load decline). Plasma-associated virus of these subjects was se-
quenced with the Sanger approach and HCV evolution under treat-
ment was investigated.
2. Materials and methods
2.1. Design of the DEB-025-HCV-203 study
The efficacy of alisporivir in combination with pegIFN-α2a in
treatment-naïve subjects was investigated in a multicenter, random-
ized, double-blind, placebo-controlled escalating dose-ranging phase
IIa study over a time period of four weeks. In total, 90 subjects in-
fected with HCV genotypes 1–4 were included, discriminating be-
tween 60 potential slow responders (56 HCV1 and 4 HCV4) and 30
potential fast responders (7 HCV2 and 23 HCV3), as stratified in a
2:1 unbalanced ratio. All subjects were randomized into four cohorts:
three double-blind, placebo-controlled cohorts of 24 subjects each (co-
horts I, II, and III) and one open non-comparative cohort of 18 subjects
(cohort IV), as specified in Fig. 1. Doses of 200, 600, and 1000 mg/
day alisporivir in combination with pegIFN-α2a 180 μg/week for four
weeks were compared with monotherapy of either 1000 mg/day al-
isporivir or 180 μg/week pegIFN-α2a. More details on treatment reg-
imen and viral load are available in Table 1. The best viral response
was obtained in cohorts II and III, with a mean drop in viral load of
about 4 log IU/ml in patients infected with HCV genotypes 1 and 4,
and of 6 log IU/ml in patients infected with HCV2 and HCV3, after
four weeks of therapy (Flisiak et al., 2009).
2.2. Selection of samples
Based on treatment status, viral load and sample availability, 58
samples originating from 25 HCV1b infected subjects were selected
for genetic sequencing, to investigate the number of changes in their
amino acid sequences under selective pressure with alisporivir alone
or combined with pegIFN-α2a. All subjects were selected based on
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Fig. 1. The study design of clinical trial DEB-025-HCV-203. Treatments were administered via four sequential cohorts of ninety treatment-naïve patients with chronic hepatitis C
in total. Cohorts I, II, and III each comprised 24 patients (18 active and 6 placebo), while cohort IV comprised 18 active patients. Within cohorts I to III, patients were randomly
assigned to one of the following treatments: cohort I received pegIFN-α2a (PEGASYS®) combined with alisporivir (200 mg), defined as 200 Combo, or pegIFN-α2a combined with
alisporivir placebo, defined as Peg Mono; cohort II: pegIFN-α2a combined with alisporivir (600 mg), defined as 600 Combo, or Peg Mono; cohort III received pegIFN-α2a combined
with alisporivir (1000 mg), defined as 1000 Combo, or Peg Mono. In cohort IV, all patients received alisporivir monotherapy (1000 mg), defined as 1000 Mono. Alisporivir was
administered twice daily from day 1 to day 7 and once daily from day 8 to day 29, while pegIFN-α2a was given subcutaneously at 180 μg/week, including on day 29. Within cohorts,
patients were stratified by HCV genotype class as potential slow responders (GTs 1, 4, 5, or 6) and potential fast responders (GTs 2 or 3) in a 2:1 unbalanced ratio. Within cohorts I to
III, patients were randomized to Combo treatment versus Peg Mono in a 3:1 ratio. Treatment duration (29 days), follow-up (3 weeks), and assessments were identical in all treatment
groups.
viral load response over a time period of 28 days, originating from the
four different cohorts of the DEB-025-HCV-203 trial.
More in detail, all selected subjects are listed in Table 1: i)
Twenty-one subjects with no or incomplete viral suppression at the
end of the treatment period (Day 29) from all four cohorts; ii) Three
subjects with complete viral suppression at Day 29 (viral load below
limit of detection, < 15 IU/ml), but detectable virus at the follow-up
visit (Day 50) (> 2 log IU/ml), from the 200 and 1000 Combo, and
1000 Mono treatment group (subjects 5202, 5501 and 1114; one from
each group); and iii) One subject with detectable virus at Day 29,
pegIFN-α2a Mono group (subject 5409).
For all subjects, two samples were selected for genetic sequenc-
ing, more specifically a baseline sample (defined as the Day 1 sample)
and an end-of-treatment sample (Day 29) or in some cases a follow-up
sample (Day 50). A follow-up sample (Day 50) was only selected in
case where the viral load of the sample at Day 29 was undetectable. Of
two subjects in which the NS5A variant D320E was identified (sub-
jects 5311 and 5415), three additional on-treatment samples (Day 8,
15 and 22) and one follow-up (Day 50) sample were analyzed, result-
ing into a total of 58 samples sequenced.
The viral load of all samples was determined using the HCV Viral
Load COBAS AMPLICOR system, from Roche Molecular Diagnos-
tics (Basel, Switzerland) and the HCV genotype using the Abbott Re-
alTime HCV Genotype assay (Santa Clara, California). Both determi-
nations were performed by MDS Pharma Services (Paris, France and
North Brunswick, New Jersey). The viral loads of the samples varied
from 35 to 5,919,998 IU/ml. The majority of the samples were EDTA
samples, for which our genetic sequencing protocols were optimized,
however some were Li-heparin samples (12/58).
2.3. Genotyping and genetic sequencing
We use the term genotyping for assays performed with the sole
purpose to determine to which genotype the HCV strains belong. The
term genetic sequencing is used for assays performed to assess amino
acid changes under treatment. The genotype of the samples was con-
firmed using a protocol based on sequencing a small region of the
NS5B gene (Arrais et al., 2008). Once the HCV genotype was con-
firmed, viral sequences were determined by using a near-full genome
HCV1b genetic sequencing method (Cuypers et al., 2014). Briefly,
RNA was extracted using the QIAamp Viral RNA mini kit (Qiagen)
and reverse transcribed with Transcriptor RT (Roche) in cDNA for
three separate regions, 5′UTR-NS2, E2-NS5A and NS4B-NS5B, par-
tially overlapping each other. Nested PCR was performed using the
Expand Long Template PCR System (Roche) for the same three re-
gions. The same (cycling) conditions were used in both PCRs. The
achieved detection limit was 570 IU/ml for the 5′UTR-NS2 region,
5670 IU/ml for E2-NS5A, while for NS4B-NS5B a detection limit of
56,670 IU/ml was obtained.
2.4. Sequencing and analyzing the sequences
Sequencing reactions were performed at Fasteris SA (Geneva,
Switzerland) using the BigDye Terminator v3.1 Cycle Sequencing kit
(Applied Biosystems Inc., Foster City, USA). Afterwards contigs were
generated and analyzed using SeqScape (Applied Biosystems Inc.,
Foster City, USA) and for each individual subject amino acid changes
during treatment were reported with respect to the baseline sequence
of that same subject.
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2.5. Phylogenetic analysis
Phylogenetic analysis was performed as part of the quality control,
to confirm the genotype and to uncover potential sample mix-up. All
NS5A-NS5B nucleotide sequences were aligned against four HCV1b
reference sequences from the Los Alamos HCV Sequence Database
(Kuiken et al., 2005), using an in-house developed pairwise align-
ment tool-chain (Cuypers et al., 2015; Libin, 2014), with the align-
ment manually edited using Seaview V4.0 (Gouy et al., 2010). A max-
imum-likelihood phylogenetic tree was constructed using RAxML
(Stamatakis, 2014), with the GTR gamma model of substitution and
1000 bootstrap replicates to evaluate the robustness of the tree. The
tree was visualized using FigTree v.1.4. (http://tree.bio.ed.ac.uk/
software/figtree/).
2.6. Analysis of the amino acid variants
In order to analyze the whole dataset, successfully amplified se-
quences were divided into four groups, according to treatment status
with a specific drug: A) All baseline sequences (of all treatment arms)
(group A, n = 21); B) All sequences after treatment of subjects receiv-
ing alisporivir monotherapy during four weeks (group B, n = 6); C)
All sequences after treatment of subjects receiving alisporivir com-
bined with pegIFN-α2a during four weeks (group C, n = 12); and
D) One sequence after treatment (Day 29) of subject 5409 receiv-
ing weekly pegIFN-α2a mono during four weeks, supplemented with
four sequences from subjects not belonging to the DEB-025-HCV-203
clinical trial but after pegIFN-α2a monotherapy for 24 weeks. Three
of these HCV1b sequences were from Genbank (Enomoto et al., 1995)
and one from an HCV1b chronically infected patient attending the
University Hospital in Leuven, for which pegIFN-α2a was combined
with ribavirin (approved by the Leuven ethical committee: ML9219,
subproject of ML8635) (group D, n = 5).
In a longitudinal analysis, amino acid changes were defined as the
number of changes at amino acid level observed between the baseline
(Day 1) and end-of-treatment sequence of the same subject, i.e. Day
29 (or follow-up sequence at Day 50 when viral load at Day 29 was
too low) counting also indels and loss or gain of polymorphisms. Since
not for all samples, the full-genome could be analyzed, due to some
sequencing failures for parts of the genome, amino acid changes were
also expressed in proportion. Standard linear regression was applied to
study the association between the proportion of amino acid changes in
the virus, and various measures of viral load for the subject in whom
those changes were found: i) the drop in viral load (log change in viral
load between baseline and Day 29), ii) the nadir viral load, iii) the vi-
ral load at baseline or iv) the viral load at Day 29. These correlations
were explored based on the assumption that viral load is a possible
measure for replication fitness, such that amino acid changes related to
viral load during HCV antiviral treatment are possibly related to drug
resistance.
In a cross-sectional analysis, Fisher's exact test was used to iden-
tify amino acid variants potentially associated with alisporivir- and in-
terferon-treatment, located in proteins NS5A and NS5B (Libin, 2014).
For assessing variants associated with alisporivir treatment, propor-
tions of amino acid variants in baseline sequences (group A), and
sequences after treatment with alisporivir (group B + C) were com-
pared; as well as group A with group B, the latter including only se-
quences under alisporivir monotherapy. For variants associated with
interferon treatment, a similar comparison was made i) comparing
baseline sequences (group A) with sequences after treatment with
pegIFN-α2a (group C + D), and ii) focusing on pegIFN-α2a
monotherapy (group A vs group D). Amino acid variants with a sig-
nificantly different proportion were used for Bayesian network (BN)
learning to study possible associations with treatment, either with al-
isporivir or interferon, using an in-house developed tool chain, follow-
ing the example of Deforche et al. (2006) and Deforche et al. (2008)
and Libin, 2014 (see Supplements).
All sequences were also scanned for the presence of prolines and
for variation around the proline sites in the genome, since cyclophilins
are peptidyl-prolyl isomerases. As alisporivir may reduce the hyper-
phosphorylated form of NS5A (Quinkert et al., 2008), the presence of
phosphorylation sites was checked, using the online available program
NetPhos 2.0 (Blom et al., 1999). All sequences were compared to ref-
erence sequence HCV1bAJ238799 (Con1 strain).
2.7. Selective pressure
Detection of selective pressure was performed using the fixed ef-
fects likelihood (FEL) method, implemented in HyPhy v2.2.1 (Pond
et al., 2005). The assumption that synonymous (dS) and non-syn-
onymous (dN) rates or dN/dS, vary among sites is premised, iterat-
ing through every codon position in the alignment to identify posi-
tions under significant positive or negative selective pressure (Pond et
al., 2009). Positions characterized by a dN/dS ratio > 1 and a p-value
< 0.05 were defined as positively selected sites, while positions with a
dN/dS ratio < 1 and a p-value < 0.05 were considered to be under neg-
ative selective pressure. To evaluate the difference in dN and dS rates
under alisporivir and interferon treatment, the same groups were com-
pared as described in Section 2.6, using the two-tailed z-test to com-
pare proportions between two groups, as implemented in Excel. Since
only one sequence from a subject treated with IFN monotherapy was
available, group D contained the four additional sequences from Gen-
bank and from the University Hospital in Leuven as described under
Section 2.6. An additional analysis was performed for subjects 5311
and 5415 harboring NS5A variant D320E, based on their NS5A-NS5B
sequences during or after alisporivir treatment (Day 8, 15, 22, 29 and
50).
3. Results
3.1. Amplification and sequencing
From the 58 samples selected, only for 41 samples all three re-
gions, 5′UTR-NS2, E2-NS5A and NS4B-NS5B could be amplified.
For ten samples not all regions could be amplified, all ten had a low
viral load (majority lower than 700 IU/ml). For four samples none
of the three regions could be amplified, for the first three samples
probably due to their low viral loads (< 350 IU/ml) and for the fourth
sample, which had a higher viral load (~ 200,000 IU/ml), amplifica-
tion failure was probably because it was a Li-heparin sample which
is known to inhibit subsequent PCR amplification. Of the follow-up
samples taken at Day 50, all characterized by a very low viral load,
for only one sample all regions could be amplified. As a result, for
only 54 of the 58 samples full or partial genome sequences could
be obtained. For the eight additional on-treatment samples of sub-
jects 5415 and 5311, in whom the viral NS5A variant D320E was ob-
served, region NS5A-NS5B was amplified successfully, with no at-
tempt to amplify other regions. Successfully amplified regions were
sequenced with the Sanger approach, of which 1.8% of runs did not
result in good quality sequences, because of poor performance of
some primers. Nevertheless there was sufficient information available
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for most regions, due to substantial overlap of sequenced fragments.
More details can be found in Table 1.
3.2. Samples excluded from analysis
For four samples of two different subjects (subjects 3302 and
3305) from the 1000 Mono group, phylogenetic analysis revealed that
probably a sample mix-up had occurred. For both subjects, the sample
indicated as baseline did not cluster with the sample indicated as Day
29 of the corresponding subject, but with the samples of the other sub-
ject. Sequencing five more samples of both subjects (screening visit
(before Day 1), Day 8, 15, 22 and 50) confirmed the switching be-
tween both baseline samples of subject 3305 and 3302 (Fig. S1). The
occurrence of a transmission chain is less likely than a sample mix-up,
since the other samples of the same subject did cluster together. Addi-
tionally, a third subject (3111) was excluded from the analysis, due to
the detection of two subtypes in its baseline sample: four sequencing
reactions indicated an infection with HCV1b, compared to all other re-
actions that pointed to HCV1a. In the sample taken at Day 29, only
HCV1b virus was observed. Sequencing this baseline sample by using
an HCV1a adapted protocol, confirmed that both viruses originated
from the same sample, suggesting that this subject had a dual infection
with subtypes HCV1a and 1b (data not shown). Thus, in total six HCV
genomes from three subjects were excluded from analysis (Table 2).
This resulted in 48 partial or full-genome sequences (Table 1), remain-
ing for further analyses. Sequences obtained in this study were sub-
mitted to Genbank (accession numbers KX258962-KX259009).
3.3. Number of changes in amino acid sequence
Amino acid sequence changes between the baseline and
end-of-treatment or follow-up sample of the same subject were in-
vestigated for 48 samples. The viral load evolution of each subject is
known over a time period of 28 days (Table 1), as well as the corre-
sponding number of changes over (a part of) the full-genome (Table
2). Only the samples of two subjects showed no changes, originat-
ing from the 1000 Mono (subject 3308) and the 200 Combo (subject
5403) group. The largest proportion of changes found was 1.9% (16
changes for subject 5501 from the 1000 Combo group), but also for
the samples of two subjects from the 1000 Mono group high propor-
tions of 0.5% (15 changes for subject 1115) and 0.6% (19 changes
for subject 5210) were identified. Most changes were loss or gain
of polymorphisms. The median proportion of amino acid changes
was compared for the four different cohorts, with respective propor-
tions of 0.23% (IQR: 0.23%–0.37%), 0.35% (0.27%–0.45%), 0.37%
(0.27%–1.14%) and 0.23% (0.08%–0.47%) for cohort 200 Combo,
600 Combo, 1000 Combo and 1000 Mono. For the subject treated with
pegIFN-α2a monotherapy (5409), 0.6% or 18 changes were detected
in the full-genome amino acid sequence, with half of them located
in the NS5A-NS5B region. Notably, about half of all full-length se-
quences displayed a higher number of changes in this region (Table
2). No significant correlations were detected between the proportion
of changes (neither full-genome, nor for the separate genes); and the
viral load at baseline, the viral load at Day 29, the drop in viral load,
or the nadir viral load.
Next, amino acid positions in NS5A-NS5B sequences significantly
associated with therapy, were investigated (Table 3). When assess-
ing variants under alisporivir treatment (see Materials and methods),
the prevalence of amino acid variants at 52 positions was signifi-
cantly different between naïve (group A) and treated (group B and
C) subjects. Focusing only on subjects treated with alisporivir
monotherapy (group A vs group B), revealed amino acid variants at 54
positions that had a significantly different prevalence, since this sec-
ond cohort was characterized by amino acid variants at five additional
positions, but missed three of the positions which were significant in
the first cohort (Table 2). Under pegIFN-α2a selective pressure, amino
acid variants at 62 positions were significantly different (group A vs
group C + D), with the majority of the positions being the same as
those of the alisporivir comparison, potentially due to the extensive
overlap in both treated subject groups (group C is present in both com-
parisons). When focusing on the five subjects treated with pegIFN-α2a
mono (group A vs group D), 56 significantly associated amino acid
positions were found, most of which overlapped with the alisporivir
comparisons. Since the majority of the significant variants are identi-
cal in all comparisons, it is not surprising that using BN learning, none
of these amino acid variants were directly connected to the treatment
node, neither for alisporivir, nor for pegIFN-α2a (Figs. S2–S3).
A proline scanning of all sequences was performed to check if an
increased variation was observed around the proline residues. No sig-
nificant differences were detected between baseline and sequences af-
ter end of therapy, neither in the position of the proline, nor in the se-
quence variation around proline. Also, no changes were observed at
phosphorylation sites (data not shown).
3.4. The amino acid variant D320E
Interestingly, the NS5A variant D320E, previously described as an
amino acid variant contributing to 3.6 fold change in alisporivir po-
tency during in vitro resistance selection with alisporivir (Coelmont
et al., 2010), was identified in two subjects from the 1000 Mono
treatment arm. For these two subjects, additional sequencing was per-
formed for the NS5A-NS5B region in samples taken at Day 8, 15, 22
and 50 (Fig. 2). These sequences were of sufficient quality to assess
whether 320E was a minority variant (represented by a quarter purple
disk), present in more or less equal proportion with the wild type (half
purple disk), or whether only 320E was detected (full purple disk).
Subject 5311 did not respond virologically, although 320E appeared
only around Day 22, constituting about half of the population at the
end of treatment (54% at Day 29), and became undetectable again off
treatment. Subject 5415 had a slow 2 log IU/ml drop in viral load by
Day 22, but rebounded at Day 29 with a virus where 320D was com-
pletely replaced with 320E, which persisted even off therapy. Stan-
dard regression analysis indicated that the presence of D320E was not
significantly associated with change in viral load (p-value = 0.54), and
viral load by itself was also unable to predict the presence of D320E
(p-value = 0.49).
3.5. Selective pressure
Using FEL, the number of positively and negatively selected po-
sitions was mapped for the full-genome sequences of the alisporivir
and interferon datasets (Table 4). The number or proportion of sites
under selective pressure was assessed, and these were compared be-
tween groups as indicated in methods. With regard to positive se-
lective pressure, very few sites were selected, with the highest num-
ber found for the baseline dataset (14 sites or 0.46%), however, there
was no significant difference neither in the number nor proportion of
sites when comparing subjects with or without drug selective pressure,
whether alisporivir or pegIFN-α2a in combination or monotherapy.
Some of the positively selected sites were common in several com-
parisons. With regard to positions under negative selective pressure,
the highest number was again observed for the baseline dataset (1282
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Fig. 2. Emergence of NS5A variant D320E in subjects 5311 and 5415. Subject 5311
did not show a virological response, its viral load remained stable and high, nevertheless
there was a clear evolution at position 320, representing about half of the viral
population at Day 29. Subject 5415 showed a 2-log transient virological response,
rebounding to pre-treatment levels when 320E emerged (320D could no longer be
detected).
sites or 42.52%), and again this was not significantly different in any
of the comparisons. It has to be noted that the baseline dataset is the
largest dataset (N = 21), with the largest power to detect sites under
positive or negative selection. Potential differences between datasets
may be masked due to their small sample sizes.
Both in the alisporivir- and IFN-treated datasets, NS5A variant
320D was found to be under negative selective pressure. Additionally,
dN/dS rates were explored for the follow-up NS5A-NS5B sequences
(Day 8, 15, 22 and 50) of the two subjects (5311 and 5415) harboring
NS5A variant D320E, revealing no positive or negative selective pres-
sure for NS5A position 320.
3.6. Other variants
Five other variants were defined by Arai et al. (2014) as possibly
conferring or enhancing resistance to CsA, more specifically T1280V
in NS3, and D2292E, D2303H, S2363G and E2414K in NS5A. From
these five mutations, variants T1280V (NS3) and D2292E (NS5A) oc-
curred in the whole dataset with a respective prevalence of 1% and
4%. Both resistance-related variants were not found to be under pos-
itive selective pressure. Subject 5411 (from the 1000 Combo group),
with a virological response of 1.6 log, presented changes at amino
acid positions previously reported during in vitro resistance selection
(Table 2), more in detail I/V298V in NS5A (with V298A observed
in vitro under alisporivir selective pressure, Neyts, 2008) and S556G
in NS5B (Fernandes et al., 2007). However, there was no correlation
between the presence of these variants, and the viral load change be-
tween baseline and Day 29, or the treatment group associated. Overall,
the prevalence of both variants at baseline was 9%, with none of them
evolving under drug selective pressure.
3.7. Resistance towards interferon
Variants possibly related with resistance to interferon (Taylor et
al., 2000; Perales et al., 2014) are located in the core region, the hy-
pervariable region-1 (HVR-1) of protein E2, and in the ISDR (inter-
feron sensitivity-determining region) and IRRDR (interferon and rib-
avirin resistance-determining region) of protein NS5A. In total, 70%
and 20% of all sequences in this study harbor the core variant 91M
or 70Q respectively, both reported as associated with IFN treatment
failure (Seko et al., 2013). Yet, no significant difference was observed
between alisporivir mono (group B) and pegIFN-α2a mono-treated
(group D) subjects for the presence of both core variants (p-value
(70Q and 91M) = 0.49). For protein NS5A, sequence heterogeneity in
the ISDR and IRRDR has been shown to be associated with a favor-
able response to IFN-based therapy (Enomoto et al., 1996; Hayashi
et al., 2011; Kozuka et al., 2012; El-Shamy et al., 2011). Since only
longitudinal data was available for one subject treated with interferon
monotherapy, the number of amino acid changes, present in both the
ISDR and IRRDR of NS5A, as well as in the HVR-1 of protein E2,
could not be compared between alisporivir- and IFN-treated subjects.
4. Discussion
To investigate the evolution of HCV during alisporivir treatment,
25 HCV1b infected subjects from the DEB-025-HCV-203 phase II
dose escalating study were studied, selecting subjects based on treat-
ment arm allocation, viral load response (no or incomplete viral sup-
pression over a time period of four weeks) and samples availability. In
total, 58 samples were genotyped, using a near-full genome sequenc-
ing approach. For each subject, a baseline sample was compared with
a sample taken at the end of the treatment period (Day 29) or at the fol-
low-up visit (Day 50). For two subjects characterized by the presence
of NS5A variant D320E, an amino acid variant known to confer low
level resistance to alisporivir in vitro, additional on-treatment samples
were sequenced. From the 25 subjects, three subjects were excluded
from the analysis, due to the occurrence of a sample mix-up and a dual
infection with HCV1a and HCV1b.
4.1. Number of changes in amino acid sequence
All subjects with available sequence information for both a base-
line and Day 29 or Day 50 sample, were checked for amino acid
changes in the full-genome or in the successfully amplified regions,
during course of treatment. Since the viral dynamic considerably
changes over an additional time period of 21 days, the comparative
analysis might have been influenced by the selection of Day 50 sam-
ples for a limited number of subjects. Nevertheless, since HCV RNA
levels were under the limit of detection for their respective Day 29
samples, and to avoid reducing the number of subjects even further,
we decided to take those Day 50 samples in order to have information
on amino acid changes for those subjects.
Although a large variation in the proportion of sequence changes
was detected, no correlation could be found between the proportion
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of changes; and the drop in viral load, the nadir viral load, the viral
load at baseline and Day 29, or the treatment arm the subject was in-
cluded in, similar to observations in a previous study (Welker et al.,
2007). Nevertheless, for the ISDR of the NS5A protein, associations
between amino acid changes and viral load levels, have been reported
(Kobayashi et al., 2002; Watanabe et al., 2003). Using a Fisher's ex-
act test, amino acid variants with significant differences in preva-
lence between baseline and post-treatment, in subjects either treated
with alisporivir and/or pegIFN-α2a, were selected. The majority of the
amino acid positions associated with treatment overlapped between al-
isporivir and pegIFN-α2a, and this may be related to the fact that they
both elicit resistance within NS5A, despite having a different mecha-
nism of action (Coelmont et al., 2010; Kozuka et al., 2012). In addi-
tion, in an association study through BN learning, none of the variants
could be linked to either alisporivir or pegIFN-α2a. However the inter-
pretation of these results is complicated, due to the extensive overlap
in subjects assigned to the alisporivir- or IFN-treated groups (N = 12),
as well as the low number of subjects treated with only one of the
two drugs in monotherapy. Only one mono pegIFN-α2a-treated sub-
ject was selected for sequencing, and the IFN monotherapy group was
therefore expanded with three additional subjects whose sequences
were deposited in Genbank, and one extra subject from a different co-
hort (Leuven University Hospital). However, since the mono-treated
groups did show many of the same amino acid positions associated
with treatment, this would suggest they may rather play a role in repli-
cation fitness. Other hypotheses should also be explored, such as ran-
dom genetic drift. To better assess their impact on treatment or fitness,
higher numbers of sequences from treated subjects are needed. The
use of Bayesian network learning in the context of HIV drug resis-
tance has proven to be able to uncover resistance-related amino acid
changes (Deforche et al., 2008).
4.2. Selective pressure
Using FEL implemented in HyPhy, sites under significant positive
or negative selective pressure could be identified in subjects treated
with alisporivir and pegIFN-α2a combined or monotherapy. Although
the number of such sites varied, there was no significant difference
between treatment regimens, and positively selected sites were few
(0.07 to 0.46%), while a substantial proportion was under negative se-
lective pressure (12.6 to 42.52%). The most striking finding of this
analysis was that despite the large number of changes under therapy,
only very few sites can be identified as being under positive selec-
tive pressure, seemingly not related to therapy, and a large proportion
of sites is under negative selective pressure even during therapy. This
observation confirmed the results of former studies which also identi-
fied a low number of positively selected positions in the HCV genome
(Cuypers et al., 2015; Gray et al., 2011; Sheridan et al., 2004; Suzuki
and Gojobori, 2001; Thomson et al., 2011), especially compared to
other viruses like HIV (12% of sites under positive selective pressure)
(Snoeck et al., 2011).
4.3. NS5A variant D320E
The first to identify the importance of NS5A variant D320E was
Goto et al. (2009), who observed that the HCV replicon with this
mutation exhibited reduced susceptibility to CsA, resulting into lim-
ited HCV RNA treatment response. This hypothesis was confirmed
by Puyang et al. (2010) who selected two NIM811-resistant clones
with six amino acid changes, and found that the level of resistance
achieved by the single D320E variant was nearly the same as that
seen with the NS5A gene containing all six mutations. Coelmont et
al. (2010) performed an in vitro selection of low-level resistance to al-
isporivir, and found D320E in NS5A. The D320E variant produced a
moderate 3.6 fold increase of EC50 for alisporivir in the HCV replicon
(Flisiak et al., 2008).
In this study, variant D320E was identified in only two subjects
(subjects 5415 and 5311) from the 1000 Mono treatment arm, while
a third subject (5210) from the same arm has been reported to harbor
D320E as a minority variant using clonal sequencing (7%, Tiongyip
et al., 2011). In subject 5415, the acquisition of D320E corresponded
to a rebound in viral load by 0.8 log IU/ml between Day 22 and Day
29, after an initial decrease in viral load of 2 log IU/ml. However, in
the case of subject 5311, the emergence of D320E did not appear to
be associated with viral load changes, as well as for subject 5210.
Given the high level of conservation of site 320 and the appearance of
320E only in subjects treated with a high dose of alisporivir, it would
seem that D320E is resulting from drug selective pressure. However,
its positive selective pressure was not strong enough to be uncovered
by our methods in this dataset. In fact, D320E was under negative se-
lective pressure in the overall analysis, suggesting it is important for
the virus to maintain D320. Yet, the persistence off therapy suggests
that this variant does not have a dramatic fitness cost, or that compen-
satory mutations have accumulated. Indeed, the development of com-
pensatory mutations for viral fitness loss due to resistance mutations
has been suggested in HCV (Di Maio et al., 2015). Similar to DAAs,
it is expected that the emergence of high level resistant strains to al-
isporivir would demonstrate a sudden loss of viral suppression. Sta-
tistical analysis indicated that the presence of D320E was not signif-
icantly associated with viral load change, and the latter was not pre-
dictive for the presence of this variant. Notably, in this study, D320E
was detected in subjects with little or no viral load reduction over four
weeks of treatment.
According to Garcia-Rivera et al. (2012), multiple mutations in the
NS5A domain II are required to confer a significant level of resis-
tance to alisporivir, for instance variant D320E combined with vari-
ant Y321N. However none of the HCV1b sequences in this study har-
bored Y321N. The additive effect of other mutations was also reported
by Tiongyip et al. (2011), which identified an increase of 4.76 fold
in EC50 for the entire mutant compared to only 2.65 fold for D320E
alone. The rather low fold change in susceptibility to alisporivir (< 3
fold change), resulting from phenotypic analyses for the subjects har-
boring variant D320E (Tiongyip et al., 2011), and the lack of associa-
tion with a change in viral load, argues against viral resistance as the
primary cause of poor response to alisporivir. Therefore, the impor-
tance of this amino acid change in alisporivir treatment still needs to
be better documented. Additionally, it was reported that alisporivir-re-
sistant clones including NS5A substitutions remained fully susceptible
to all three DAA classes as well as that subjects bearing major DAA
resistant variants to all three DAA classes can still be treated with al-
isporivir (Tiongyip et al., 2011).
4.4. Other variants
Arai et al. (2014) reported five other mutations possibly confer-
ring or enhancing resistance to CsA, of which four were located in
the NS5A protein and the fifth in the NS3 region. Only two of them
were found in this study, more in detail the NS3 variant T1280V and
variant D2292E in NS5A, detected in respectively 1% and 4% of all
sequences. Further, none of the other viral changes found were previ-
ously reported as being associated with resistance against alisporivir
(Kaul, 2008; Snoeck, 2009) or against other cyclophilin inhibitors in
vitro (Fernandes et al., 2007; Hopkins et al., 2012; Puyang et al.,
2010; Robida et al., 2007). Although a subject was detected with a
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virus that showed variation on previously described amino acid posi-
tions 298 in NS5A and 556 in NS5B, also here no statistical significant
correlations were detected between changes at one of these positions
and change in viral load.
4.5. Resistance to interferon
Several variants have been reported to be potentially related with
resistance to IFN (Perales et al., 2014; Taylor et al., 2000), in the
core protein variants 91M and 70Q (Seko et al., 2013), the hypervari-
able region-1 (HVR-1) of protein E2, and sequence variation in the
ISDR (interferon sensitivity-determining region) and the IRRDR (in-
terferon and ribavirin resistance-determining region) of protein NS5A
(El-Shamy et al., 2011; Hayashi et al., 2011; Kozuka et al., 2012).
Subject 5409, only treated with interferon, harbored 18 amino acid
changes in the full-genome of HCV1b, of which nine were located in
the NS5A-NS5B genes. One of these was 91M in the core protein,
however, more than half of all studied subjects harbored this specific
variant. However, no significant differences were detected when com-
paring subjects treated with alisporivir and/or interferon, which could
be due to the low number of sequences under selective pressure with
alisporivir or pegIFN-α2a monotherapy.
5. Conclusion
The study DEB-025-203 was too small to make any statistically
significant conclusions on amino acid changes that could be associ-
ated with virological response or failure. Interestingly, variant D320E
in NS5A, previously detected during in vitro resistance selection, was
identified in two subjects treated with alisporivir monotherapy, how-
ever associated with only a small increase in viral load in one subject,
not found to be positively selected, and displaying only a limited phe-
notypic effect (Tiongyip et al., 2011). Although the majority of HCV
patients treated with DAA combinations seem to eradicate the virus,
these results indicate that host targeting antivirals can still be of impor-
tance in the cure of potential hard-to-treat HCV patient populations.
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